News Details - novonordisk.com
Sep 20, 2024 · Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed. Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 …
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity …
NVO. Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1)...
Monlunabant phase 2a trial in obesity successfully completed
Sep 20, 2024 · Monlunabant phase 2a trial in obesity successfully completed. Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 …
Questions over Novo Nordisk $1bn weight loss drug after Phase …
Sep 23, 2024 · Novo Nordisk acquired monlunabant in a $1bn deal last year, but the Phase IIa trial raises questions over the efficacy and safety ratio.
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity …
Based on the results, Novo Nordisk expects to initiate a larger phase 2b trial in obesity to further investigate dosing and the safety profile of monlunabant over a longer duration in a global...
News Details - novonordisk.com
Nov 6, 2024 · Within R&D, Novo Nordisk completed the phase 2a trial with monlunabant in obesity and expects to initiate a larger phase 2b trial in obesity in 2025 to further investigate the dosing and safety profile of monlunabant over a longer duration in a global population.
Novo Nordisk A/S, Monlunabant phase 2a trial in obesity …
Sep 23, 2024 · Bagsvaerd, Denmark - Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 inverse agonist.
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity …
Sep 20, 2024 · The trial investigated the efficacy and safety of a once-daily 10 mg, 20 mg and 50 mg dose of monlunabant compared to placebo on body weight after 16 weeks in 243 people with obesity and...
Novo Shares Fall on Safety Data for New Weight-Loss Drug - Bloomberg.com
Sep 20, 2024 · Shares of Novo Nordisk A/S fell after the Danish drugmaker reported mixed safety data on one of its next-generation weight-loss drugs. A mid-stage trial showed that monlunabant helped...
Novo Nordisk affirms 25% weight-loss expectation for …
Nov 6, 2024 · Novo Nordisk has previously said that CagriSema has a potential of up to 25% weight loss, compared with the 15% weight loss of Wegovy. Lange said on Wednesday the company still expects the data ...